JP2014114295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014114295A5 JP2014114295A5 JP2014004320A JP2014004320A JP2014114295A5 JP 2014114295 A5 JP2014114295 A5 JP 2014114295A5 JP 2014004320 A JP2014004320 A JP 2014004320A JP 2014004320 A JP2014004320 A JP 2014004320A JP 2014114295 A5 JP2014114295 A5 JP 2014114295A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- nspaccha
- unit form
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 6
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 6
- 229960003530 donepezil Drugs 0.000 claims 6
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 4
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 3
- 230000001078 anti-cholinergic effect Effects 0.000 claims 3
- 229960004136 rivastigmine Drugs 0.000 claims 3
- 229960003980 galantamine Drugs 0.000 claims 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960003855 solifenacin Drugs 0.000 claims 2
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims 2
- 229960001491 trospium Drugs 0.000 claims 2
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003551 muscarinic effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 229960003510 propiverine Drugs 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08005750 | 2008-03-27 | ||
| EP08005750.8 | 2008-03-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501792A Division JP5647099B2 (ja) | 2008-03-27 | 2009-03-17 | 認知症を治療するための使用及び組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016078787A Division JP6427522B2 (ja) | 2008-03-27 | 2016-04-11 | 認知症を治療するための使用及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014114295A JP2014114295A (ja) | 2014-06-26 |
| JP2014114295A5 true JP2014114295A5 (OSRAM) | 2015-02-19 |
Family
ID=39535697
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501792A Expired - Fee Related JP5647099B2 (ja) | 2008-03-27 | 2009-03-17 | 認知症を治療するための使用及び組成物 |
| JP2014004320A Pending JP2014114295A (ja) | 2008-03-27 | 2014-01-14 | 認知症を治療するための使用及び組成物 |
| JP2016078787A Expired - Fee Related JP6427522B2 (ja) | 2008-03-27 | 2016-04-11 | 認知症を治療するための使用及び組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501792A Expired - Fee Related JP5647099B2 (ja) | 2008-03-27 | 2009-03-17 | 認知症を治療するための使用及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016078787A Expired - Fee Related JP6427522B2 (ja) | 2008-03-27 | 2016-04-11 | 認知症を治療するための使用及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US8404701B2 (OSRAM) |
| EP (3) | EP2271218B1 (OSRAM) |
| JP (3) | JP5647099B2 (OSRAM) |
| AU (1) | AU2009229372C1 (OSRAM) |
| CA (1) | CA2718411C (OSRAM) |
| DK (1) | DK2271218T3 (OSRAM) |
| ES (1) | ES2634421T3 (OSRAM) |
| MX (3) | MX347901B (OSRAM) |
| PL (1) | PL2271218T3 (OSRAM) |
| WO (1) | WO2009120277A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8969402B2 (en) | 2006-11-15 | 2015-03-03 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| DK2271218T3 (en) * | 2008-03-27 | 2017-09-11 | Chase Pharmaceuticals Corp | USE AND COMPOSITION TO TREAT DEMENS |
| US20110201597A1 (en) | 2008-03-27 | 2011-08-18 | Chase Thomas N | Method and composition for treating alzheimer-type dementia |
| PL3061821T3 (pl) | 2009-07-22 | 2020-01-31 | PureTech Health LLC | Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego |
| MX345236B (es) | 2009-09-18 | 2017-01-23 | Chase Pharmaceuticals Corp | Metodo y composicion para tratar la demencia de tipo alzheimer. |
| JP2011213606A (ja) * | 2010-03-31 | 2011-10-27 | Sawai Pharmaceutical Co Ltd | ドネペジルを含有する固形製剤の製造方法 |
| JP2011213695A (ja) * | 2010-04-02 | 2011-10-27 | Taisho Pharm Ind Ltd | ドネペジル塩酸塩含有口腔内速崩壊錠 |
| WO2014039627A1 (en) | 2012-09-05 | 2014-03-13 | Chase Pharmaceuticals Corporation | Anticholinergic neuroprotective composition and methods |
| EP3242659A4 (en) | 2015-01-09 | 2018-09-12 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system combination |
| EP3265466A4 (en) * | 2015-03-06 | 2018-12-26 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
| US10307409B2 (en) * | 2015-03-06 | 2019-06-04 | Chase Pharmaceuticals Corporation | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system |
| CA2978201A1 (en) | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Use of oxybutynin transdermal formulations to reduce side effects associated with muscarinic agonists |
| ES2942176T3 (es) | 2015-06-15 | 2023-05-30 | Qaam Pharmaceuticals Llc | Sales de ácidos grasos de glicopirronio y métodos para su elaboración |
| WO2017015349A1 (en) * | 2015-07-20 | 2017-01-26 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| WO2017044693A1 (en) | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| WO2017147104A1 (en) * | 2016-02-24 | 2017-08-31 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combinations |
| US10479706B2 (en) * | 2016-06-03 | 2019-11-19 | Katz Water Tech, Llc | Apparatus, method and system for desalinating water |
| WO2018081508A1 (en) * | 2016-10-28 | 2018-05-03 | Chase Pharmaceutical Corporation | Memantine combinations and use |
| WO2019201755A1 (en) * | 2018-04-17 | 2019-10-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the transdermal administration of solifenacin |
| JP7096441B2 (ja) | 2018-09-28 | 2022-07-05 | カルナ セラピューティックス，インコーポレイテッド | ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法 |
| US20240024261A1 (en) * | 2020-09-21 | 2024-01-25 | Dr. Raymond Lab Inc | Pharmaceutical composition for improving cognitive ability or enhancing memory |
| JP7755874B2 (ja) * | 2020-11-26 | 2025-10-17 | 寧康瑞珠生物制薬（珠海）有限公司 | 抗コリン剤 |
| US12109202B2 (en) | 2021-01-29 | 2024-10-08 | Qaam Pharmaceuticals, Llc | Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB795758A (en) | 1955-08-22 | 1958-05-28 | Pfizer & Co C | Amino esters and the preparation thereof |
| US3480626A (en) | 1967-05-18 | 1969-11-25 | Chem Fab Dr R Pfleger | Certain azoniaspironortropine derivatives |
| GB1204580A (en) | 1968-10-05 | 1970-09-09 | Aspro Nicholas Ltd | Pharmaceutical dosage forms |
| US3576388A (en) | 1968-12-05 | 1971-04-27 | Stauffer Wacker Silicone Corp | Electrical cable |
| DD106643A1 (OSRAM) | 1973-07-12 | 1974-06-20 | ||
| US4965074A (en) | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| US4798841A (en) | 1987-03-31 | 1989-01-17 | Warner-Lambert Company | Tetrahydropyridine oxime cholinergic agents and method of treatment |
| GB8717446D0 (en) | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US5382600A (en) | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| US4937239A (en) | 1989-02-13 | 1990-06-26 | Warner-Lambert Company | Azabicycloalkane oxime & azabicycloalkene oxime muscarinic agents |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| GB9612710D0 (en) | 1996-06-18 | 1996-08-21 | Pfizer Ltd | Method of treatment |
| AU749088C (en) | 1997-07-09 | 2005-11-03 | Axonyx, Inc. | Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer's disease and dementias |
| EP0976404A3 (en) | 1998-07-30 | 2001-06-27 | Pfizer Products Inc. | A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal |
| CA2310926C (en) | 2000-04-03 | 2002-10-15 | Janssen Pharmaceutica N.V. | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| WO2002072093A2 (en) * | 2001-02-08 | 2002-09-19 | Schering Corporation | Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders |
| US8216609B2 (en) * | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| US7427280B2 (en) * | 2002-09-06 | 2008-09-23 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues |
| US6974820B2 (en) | 2002-11-06 | 2005-12-13 | Bridge Pharma, Inc. | Methods for treating urinary incontinence and other disorders using trospium |
| CN1520818A (zh) | 2003-02-09 | 2004-08-18 | 山东绿叶天然药物研究开发有限公司 | 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物 |
| US8299062B2 (en) | 2003-09-17 | 2012-10-30 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
| GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| DE602005016775D1 (de) | 2004-01-16 | 2009-11-05 | Wyeth Corp | Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion |
| KR20060124712A (ko) | 2004-02-20 | 2006-12-05 | 노파르티스 아게 | 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제 |
| AR051950A1 (es) | 2004-11-10 | 2007-02-21 | Osmotica Pharmaceutical Argent | Comprimido multicapa con capas que se separan |
| KR100866720B1 (ko) | 2004-12-27 | 2008-11-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항치매 약물의 안정화 방법 |
| US7390816B2 (en) | 2005-06-21 | 2008-06-24 | Bridge Pharma, Inc. | Methods for treating urinary incontinence in patients suffering from memory disorders |
| US20070004766A1 (en) | 2005-07-01 | 2007-01-04 | Aberg A K G | Methods for relaxation of smooth muscle contractions using Trospium |
| US20070224259A1 (en) | 2005-09-21 | 2007-09-27 | Gupta Anil K | Anti-inflammatory pharmaceutical composition |
| EP1933809B1 (en) | 2005-10-11 | 2012-02-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
| EP2010478A1 (en) * | 2006-04-21 | 2009-01-07 | Wyeth | Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof |
| AU2007294968A1 (en) | 2006-09-12 | 2008-03-20 | Adolor Corporation | Use of N-containing spirocompounds for the enhancement of cognitive function |
| US20080090808A1 (en) | 2006-10-17 | 2008-04-17 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
| US8097633B2 (en) * | 2006-11-15 | 2012-01-17 | Rich Steven A | Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium |
| DK2271218T3 (en) * | 2008-03-27 | 2017-09-11 | Chase Pharmaceuticals Corp | USE AND COMPOSITION TO TREAT DEMENS |
| MX345236B (es) * | 2009-09-18 | 2017-01-23 | Chase Pharmaceuticals Corp | Metodo y composicion para tratar la demencia de tipo alzheimer. |
-
2009
- 2009-03-17 DK DK09726036.8T patent/DK2271218T3/en active
- 2009-03-17 CA CA2718411A patent/CA2718411C/en active Active
- 2009-03-17 US US12/934,140 patent/US8404701B2/en active Active
- 2009-03-17 MX MX2014004035A patent/MX347901B/es unknown
- 2009-03-17 ES ES09726036.8T patent/ES2634421T3/es active Active
- 2009-03-17 EP EP09726036.8A patent/EP2271218B1/en not_active Revoked
- 2009-03-17 JP JP2011501792A patent/JP5647099B2/ja not_active Expired - Fee Related
- 2009-03-17 PL PL09726036T patent/PL2271218T3/pl unknown
- 2009-03-17 EP EP22177194.2A patent/EP4088717A1/en not_active Withdrawn
- 2009-03-17 MX MX2010010460A patent/MX2010010460A/es active IP Right Grant
- 2009-03-17 WO PCT/US2009/001662 patent/WO2009120277A1/en not_active Ceased
- 2009-03-17 EP EP17150365.9A patent/EP3178477A1/en not_active Withdrawn
- 2009-03-17 MX MX2013009019A patent/MX344177B/es unknown
- 2009-03-17 AU AU2009229372A patent/AU2009229372C1/en not_active Ceased
-
2013
- 2013-02-12 US US13/765,240 patent/US20130158012A1/en not_active Abandoned
-
2014
- 2014-01-14 JP JP2014004320A patent/JP2014114295A/ja active Pending
- 2014-05-29 US US14/290,123 patent/US9044472B2/en active Active
-
2015
- 2015-04-27 US US14/696,861 patent/US20150224096A1/en not_active Abandoned
-
2016
- 2016-04-11 JP JP2016078787A patent/JP6427522B2/ja not_active Expired - Fee Related
-
2018
- 2018-11-21 US US16/198,517 patent/US20190091214A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014114295A5 (OSRAM) | ||
| JP2013542261A5 (OSRAM) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2016535795A5 (OSRAM) | ||
| JOP20130256B1 (ar) | مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي | |
| MX385976B (es) | Composicion neuroprotectora anticolinergica y metodos | |
| EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| TN2017000535A1 (en) | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| JP2013542247A5 (OSRAM) | ||
| JP2015509535A5 (OSRAM) | ||
| RU2018106453A (ru) | Соединения | |
| IN2014MN01755A (OSRAM) | ||
| JP2013510120A5 (OSRAM) | ||
| EA201491329A1 (ru) | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| JP2017518334A5 (OSRAM) | ||
| JP2014511892A5 (OSRAM) | ||
| PE20120989A1 (es) | Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo | |
| JP2016540742A5 (OSRAM) | ||
| JP2017531033A5 (OSRAM) | ||
| JP2016510326A5 (OSRAM) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| HK1210771A1 (zh) | 氮杂吲哚衍生物 | |
| JP2014507477A5 (OSRAM) | ||
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| JP2016539157A5 (OSRAM) |